Akari Therapeutics Plc
(NASDAQ : AKTX)

( )
AKTX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
-0.50%130.670.7%$876.22m
PFEPfizer Inc.
0.53%36.300.9%$660.82m
MRKMerck & Co., Inc.
0.40%84.680.7%$645.76m
ABBVAbbVie, Inc.
0.19%73.772.3%$552.14m
BMYBristol-Myers Squibb Company
-0.12%51.551.4%$505.04m
LLYEli Lilly and Company
-0.42%107.911.0%$305.36m
NVSNovartis AG Sponsored ADR
-0.77%85.930.2%$146.48m
AZNAstraZeneca PLC Sponsored ADR
0.60%43.841.2%$143.40m
GSKGlaxoSmithKline plc Sponsored ADR
-0.02%42.170.3%$93.41m
SNYSanofi Sponsored ADR
-0.13%44.890.2%$80.41m
NVONovo Nordisk A/S Sponsored ADR Class B
1.60%52.050.1%$71.85m
LCILannett Company, Inc.
-2.17%10.8235.6%$16.01m
AKTXAkari Therapeutics Plc Sponsored ADR
-1.65%1.791.6%$0.58m
EPIXESSA Pharma Inc
0.00%3.300.1%$0.09m

Company Profile

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.